Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharma (PCRX) Tops Q2 EPS by 6c, Revenues Beat; Provides FY19 Sales Outlook
August 8, 2019 8:04 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $102.6 million versus the consensus estimate of $100.45 million.
Second Quarter 2019 Financial Results
Total revenues were $102.6 million in the second quarter of 2019, a 22 percent increase over the $84.1 million reported for the second quarter of 2018.Total net product sales were $101.8 million in the second quarter of 2019, a 26 percent increase over the $80.7 million reported for the second quarter of 2018.Net product sales of EXPAREL/bupivacaine liposome injectable suspension were $99.8 million in the second... More